Clinical trials
Advanced Solid Cancer clinical trials
Below are recruiting advanced solid cancer clinical trials, each written for real people, not researchers. We’re tracking 1,326 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03514368Recruiting
Testing immune markers to track cancer treatment safety and benefit
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
ToulouseAges 18 years+ - NCT06466265RecruitingPhase 1
Testing DNP002 for advanced solid tumors that have not responded to standard treatments
This trial tests a new drug called DNP002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if DNP002 is safe and can help shrink tumors or slow their growth.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT05719558RecruitingPhase 1
Study of ASP1002 for adults with solid tumors
This trial tests a new drug called ASP1002, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to see if ASP1002 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT05785741RecruitingPhase 1/Phase 2
DB-1310 for advanced solid tumors after standard treatment fails
This early-phase study tests DB-1310 in people with advanced or metastatic solid cancers that have come back or worsened after standard treatments. It aims to find the safest dose and whether it can help shrink tumors or slow cancer growth.
Sacramento, CaliforniaAges 18 years+ - NCT05914116RecruitingPhase 1/Phase 2
Early study of DB-1311 with BNT324 for advanced solid tumors
This Phase 1/2a study tests a combination treatment (DB-1311 with BNT324) in people with advanced or metastatic solid cancers that have grown despite standard treatments. It aims to find a safe dose and look for signs the treatment can shrink tumors or slow growth.
Tucson, ArizonaAges 18 years+ - NCT07523529RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Solid Tumors
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Shenzhen, GuangdongAges 18–75 - NCT07027488RecruitingPhase 1
Testing AB821 for advanced solid tumors that resist immunotherapy
This trial tests a new study drug, AB821, for people with advanced solid tumors that have stopped responding to standard treatments, especially immunotherapy. The goal is to see if AB821 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT06475300RecruitingPhase 2
BL-B01D1 plus immunotherapy for advanced lung and throat cancers
This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.
Guangzhou, GuangdongAges 18 years+ - NCT05403554RecruitingPhase 1
Testing a new mesothelin-targeting drug for certain solid cancers
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
ParisAges 18 years+ - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05620732Recruiting
CAR-T treatment for advanced stomach or pancreatic cancer
This trial tests a customized immune-cell treatment (CAR-T) for advanced stomach or pancreatic cancer that cannot be removed by surgery. It aims to use cells engineered to target a specific tumor marker to shrink cancer or slow its growth.
Shenzhen, GuangdongAges 18–75 - NCT06010862RecruitingPhase 1
CAR-T therapy for CEA-positive advanced cancers
This trial tests a new type of immune cell therapy (called CAR-T) that targets a protein called CEA on cancer cells. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried standard treatments without success.
Nanchang, JiangxiAges 18 years+ - NCT07544056RecruitingPhase 2/Phase 3
BEBT-209 Plus Chemotherapy for Triple-Negative Breast Cancer
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT04515810Recruiting
Mobile app coaching for planning care after serious cancer
This study tests a mobile health app (PACT) to help people with advanced cancer talk and plan for future care. It may help you and a loved one stay engaged in advance care planning (planning what care you want and who should speak for you).
Manhasset, New YorkAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT06364410RecruitingPhase 1
Testing a new drug combo for stomach and other solid tumors
This trial tests a combination of two drugs, trastuzumab deruxtecan and azenosertib, for people with stomach cancer or other solid tumors that have a specific protein called HER2. It aims to see if this combination can help when other treatments have stopped working.
Houston, TexasAges 18 years+ - NCT06984562Recruiting
Adaptive radiation therapy for advanced pancreatic cancer
This trial tests a new way of giving radiation therapy that adapts to changes in your cancer over time. It is for people with pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Phoenix, ArizonaAges 18 years+ - NCT06482086RecruitingPhase 2
Using tumor models to guide drug choice for advanced thyroid cancer
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
Chengdu, SichuanAges 18 years+ - NCT06063681RecruitingPhase 1
Testing a new ENPPI inhibitor for advanced solid tumors
This trial tests a new drug, SR-8541A, that blocks an enzyme called ENPPI, which may help slow or stop tumor growth. It is for people with advanced or metastatic solid tumors who have not responded to other treatments or have no standard options.
Randwick, New South WalesAges 18 years+ - NCT06288373RecruitingPhase 2/Phase 3
Comparing chemoimmunotherapy vs chemoradiation for advanced cervical cancer before surgery
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
Hefei, AnhuiAges 18–70 - NCT06288360RecruitingPhase 2
Chemo plus immunotherapy before surgery for PD-L1-negative cervical cancer
This trial tests whether combining chemotherapy with immunotherapy before surgery can help treat cervical cancer that is PD-L1 negative. It's for women with larger tumors (stage IB3 to IIB) who have not been treated yet.
Hefei, AnhuiAges 18–70 - NCT07455617RecruitingPhase 1
Vaccine for KRAS-mutated advanced solid tumors
This trial tests a new vaccine, ABO2102, for people with advanced solid tumors that have a specific change in the KRAS gene. The vaccine aims to help your immune system fight the cancer.
ShanghaiAges 18 years+ - NCT06797336RecruitingPhase 1
Study of PT0253 for advanced KRAS G12D mutated tumors
This trial tests an experimental drug called PT0253 for people with advanced or metastatic cancers that have a specific genetic change called KRAS G12D. The drug may help shrink or slow the growth of these tumors, and the study will also check for side effects.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid cancer?
- Yes. Clin2 currently lists 1,326 recruiting advanced solid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.